Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Outperform on Spruce Biosciences, Maintains $8 Price Target By Benzinga Newsdesk March 20, 8:51 AM RBC Capital analyst Gregory Renza reiterates Spruce Biosciences (NASDAQ:SPRB) with a Outperform and maintains $8 price target. SPRB
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Outperform on Aptiv, Maintains $128 Price Target By Benzinga Newsdesk March 20, 8:47 AM RBC Capital analyst Tom Narayan reiterates Aptiv (NYSE:APTV) with a Outperform and maintains $128 price target. APTV
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Sector Perform on Algonquin Power, Maintains $8 Price Target By Benzinga Newsdesk March 20, 8:43 AM RBC Capital analyst Nelson Ng reiterates Algonquin Power (NYSE:AQN) with a Sector Perform and maintains $8 price target. AQN
Read More 1 minute read Analyst Ratings News Price Target Reiteration Cantor Fitzgerald Reiterates Overweight on Immunome, Maintains $8 Price Target By Benzinga Newsdesk March 20, 8:21 AM Cantor Fitzgerald analyst Pete Stavropoulos reiterates Immunome (NASDAQ:IMNM) with a Overweight and maintains $8 price target. IMNM
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $20 Price Target By Benzinga Newsdesk March 20, 7:51 AM HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $20 price target. ASLN
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on DICE Therapeutics, Maintains $60 Price Target By Benzinga Newsdesk March 20, 7:14 AM HC Wainwright & Co. analyst Emily Bodnar reiterates DICE Therapeutics (NASDAQ:DICE) with a Buy and maintains $60 price target. DICE
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Kinnate Biopharma, Maintains $33 Price Target By Benzinga Newsdesk March 20, 7:10 AM HC Wainwright & Co. analyst Robert Burns reiterates Kinnate Biopharma (NASDAQ:KNTE) with a Buy and maintains $33 price target. KNTE
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $64 Price Target By Benzinga Newsdesk March 20, 7:08 AM HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $64 price target. AKRO
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Genius Sports, Maintains $7 Price Target By Benzinga Newsdesk March 20, 6:54 AM Needham analyst Bernie McTernan reiterates Genius Sports (NYSE:GENI) with a Buy and maintains $7 price target. GENI
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Datadog, Maintains $105 Price Target By Benzinga Newsdesk March 20, 5:52 AM Needham analyst Mike Cikos reiterates Datadog (NASDAQ:DDOG) with a Buy and maintains $105 price target. DDOG